Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Pharmacological manipulation of the RAR/RXR signaling pathway maintains the repopulating capacity of hematopoietic stem cells in culture.

Safi R, Muramoto GG, Salter AB, Meadows S, Himburg H, Russell L, Daher P, Doan P, Leibowitz MD, Chao NJ, McDonnell DP, Chute JP.

Mol Endocrinol. 2009 Feb;23(2):188-201. doi: 10.1210/me.2008-0121. Epub 2008 Dec 23.

2.

LGD-5552, an antiinflammatory glucocorticoid receptor ligand with reduced side effects, in vivo.

López FJ, Ardecky RJ, Bebo B, Benbatoul K, De Grandpre L, Liu S, Leibowitz MD, Marschke K, Rosen J, Rungta D, Viveros HO, Yen WC, Zhi L, Negro-Vilar A, Miner JN.

Endocrinology. 2008 May;149(5):2080-9. doi: 10.1210/en.2007-1353. Epub 2008 Jan 24.

PMID:
18218700
3.

RAR and RXR modulation in cancer and metabolic disease.

Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H.

Nat Rev Drug Discov. 2007 Oct;6(10):793-810. Review.

PMID:
17906642
4.

Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes.

Leibowitz MD, Ardecky RJ, Boehm MF, Broderick CL, Carfagna MA, Crombie DL, D'Arrigo J, Etgen GJ, Faul MM, Grese TA, Havel H, Hein NI, Heyman RA, Jolley D, Klausing K, Liu S, Mais DE, Mapes CM, Marschke KB, Michellys PY, Montrose-Rafizadeh C, Ogilvie KM, Pascual B, Rungta D, Tyhonas JS, Urcan MS, Wardlow M, Yumibe N, Reifel-Miller A.

Endocrinology. 2006 Feb;147(2):1044-53. Epub 2005 Nov 3.

PMID:
16269450
5.

Design and synthesis of benzofused heterocyclic RXR modulators.

Gernert DL, Neel DA, Boehm MF, Leibowitz MD, Mais DA, Michellys PY, Rungta D, Reifel-Miller A, Grese TA.

Bioorg Med Chem Lett. 2004 Jun 7;14(11):2759-63.

PMID:
15125928
6.

Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis.

Kast-Woelbern HR, Dana SL, Cesario RM, Sun L, de Grandpre LY, Brooks ME, Osburn DL, Reifel-Miller A, Klausing K, Leibowitz MD.

J Biol Chem. 2004 Jun 4;279(23):23908-15. Epub 2004 Apr 8.

7.

Design, synthesis and structure-activity relationship of novel RXR-selective modulators.

Michellys PY, D'Arrigo J, Grese TA, Karanewsky DS, Leibowitz MD, Mais DA, Mapes CM, Reifel-Miller A, Rungta D, Boehm MF.

Bioorg Med Chem Lett. 2004 Mar 22;14(6):1593-8.

PMID:
15006411
8.

Effects of rexinoids on glucose transport and insulin-mediated signaling in skeletal muscles of diabetic (db/db) mice.

Shen Q, Cline GW, Shulman GI, Leibowitz MD, Davies PJ.

J Biol Chem. 2004 May 7;279(19):19721-31. Epub 2004 Mar 2.

9.

Activation of the retinoid X receptor suppresses appetite in the rat.

Ogilvie KM, Saladin R, Nagy TR, Urcan MS, Heyman RA, Leibowitz MD.

Endocrinology. 2004 Feb;145(2):565-73. Epub 2003 Nov 6.

PMID:
14605005
10.

Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.

Michellys PY, Boehm MF, Chen JH, Grese TA, Karanewsky DS, Leibowitz MD, Liu S, Mais DA, Mapes CM, Reifel-Miller A, Ogilvie KM, Rungta D, Thompson AW, Tyhonas JS, Yumibe N, Ardecky RJ.

Bioorg Med Chem Lett. 2003 Nov 17;13(22):4071-5.

PMID:
14592510
11.

Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.

Michellys PY, Ardecky RJ, Chen JH, D'Arrigo J, Grese TA, Karanewsky DS, Leibowitz MD, Liu S, Mais DA, Mapes CM, Montrose-Rafizadeh C, Ogilvie KM, Reifel-Miller A, Rungta D, Thompson AW, Tyhonas JS, Boehm MF.

J Med Chem. 2003 Sep 11;46(19):4087-103.

PMID:
12954061
12.

Design and synthesis of fluorinated RXR modulators.

Gernert DL, Ajamie R, Ardecky RA, Bell MG, Leibowitz MD, Mais DA, Mapes CM, Michellys PY, Rungta D, Reifel-Miller A, Tyhonas JS, Yumibe N, Grese TA.

Bioorg Med Chem Lett. 2003 Oct 6;13(19):3191-5.

PMID:
12951091
13.

Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.

Michellys PY, Ardecky RJ, Chen JH, Crombie DL, Etgen GJ, Faul MM, Faulkner AL, Grese TA, Heyman RA, Karanewsky DS, Klausing K, Leibowitz MD, Liu S, Mais DA, Mapes CM, Marschke KB, Reifel-Miller A, Ogilvie KM, Rungta D, Thompson AW, Tyhonas JS, Boehm MF.

J Med Chem. 2003 Jun 19;46(13):2683-96.

PMID:
12801232
14.

Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat.

Liu S, Ogilvie KM, Klausing K, Lawson MA, Jolley D, Li D, Bilakovics J, Pascual B, Hein N, Urcan M, Leibowitz MD.

Endocrinology. 2002 Aug;143(8):2880-5.

PMID:
12130551
15.

Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies.

Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, Derijard B, Desvergne B, Wahli W, Chambon P, Leibowitz MD, Colombel JF, Auwerx J.

J Exp Med. 2001 Apr 2;193(7):827-38.

16.

Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.

Singh Ahuja H, Liu S, Crombie DL, Boehm M, Leibowitz MD, Heyman RA, Depre C, Nagy L, Tontonoz P, Davies PJ.

Mol Pharmacol. 2001 Apr;59(4):765-73.

PMID:
11259621
17.

Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor.

Claudel T, Leibowitz MD, Fiévet C, Tailleux A, Wagner B, Repa JJ, Torpier G, Lobaccaro JM, Paterniti JR, Mangelsdorf DJ, Heyman RA, Auwerx J.

Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2610-5. Epub 2001 Feb 20.

18.

Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity.

Davies PJ, Berry SA, Shipley GL, Eckel RH, Hennuyer N, Crombie DL, Ogilvie KM, Peinado-Onsurbe J, Fievet C, Leibowitz MD, Heyman RA, Auwerx J.

Mol Pharmacol. 2001 Feb;59(2):170-6.

PMID:
11160850
19.

[Peroxisome proliferator-activated receptor (PPAR) gamma: a new target for the treatment of inflammatory bowel disease].

Dubuquoy L, Bourdon C, Peuchmaur M, Leibowitz MD, Nutten S, Colombel JF, Auwerx J, Desreumaux P.

Gastroenterol Clin Biol. 2000 Aug-Sep;24(8-9):719-24. French.

20.

A PPARgamma mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus.

Berger J, Patel HV, Woods J, Hayes NS, Parent SA, Clemas J, Leibowitz MD, Elbrecht A, Rachubinski RA, Capone JP, Moller DE.

Mol Cell Endocrinol. 2000 Apr 25;162(1-2):57-67.

PMID:
10854698
21.

Activation of PPARdelta alters lipid metabolism in db/db mice.

Leibowitz MD, Fiévet C, Hennuyer N, Peinado-Onsurbe J, Duez H, Bergera J, Cullinan CA, Sparrow CP, Baffic J, Berger GD, Santini C, Marquis RW, Tolman RL, Smith RG, Moller DE, Auwerx J.

FEBS Lett. 2000 May 19;473(3):333-6.

22.

Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects.

Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y, Tanen M, Ventre J, Wu MS, Berger GD, Mosley R, Marquis R, Santini C, Sahoo SP, Tolman RL, Smith RG, Moller DE.

J Biol Chem. 1999 Mar 5;274(10):6718-25.

23.

Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.

Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD.

Endocrinology. 1996 Oct;137(10):4189-95.

PMID:
8828476
24.

Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2.

Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz Md, Moller DE, Berger J.

Biochem Biophys Res Commun. 1996 Jul 16;224(2):431-7.

PMID:
8702406
25.

Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice.

Zhang B, Graziano MP, Doebber TW, Leibowitz MD, White-Carrington S, Szalkowski DM, Hey PJ, Wu M, Cullinan CA, Bailey P, Lollmann B, Frederich R, Flier JS, Strader CD, Smith RG.

J Biol Chem. 1996 Apr 19;271(16):9455-9.

26.

A novel insulin secretagogue is a phosphodiesterase inhibitor.

Leibowitz MD, Biswas C, Brady EJ, Conti M, Cullinan CA, Hayes NS, Manganiello VC, Saperstein R, Wang LH, Zafian PT, et al.

Diabetes. 1995 Jan;44(1):67-74.

PMID:
7813816
27.

Isolation of myocardial L-type calcium channel gating currents with the spider toxin omega-Aga-IIIA.

Ertel EA, Smith MM, Leibowitz MD, Cohen CJ.

J Gen Physiol. 1994 May;103(5):731-53.

28.

Glucose-dependent alterations of intracellular free calcium by glucagon-like peptide-1(7-36amide) in individual ob/ob mouse beta-cells.

Cullinan CA, Brady EJ, Saperstein R, Leibowitz MD.

Cell Calcium. 1994 May;15(5):391-400.

PMID:
8033197
29.

High affinity block of myocardial L-type calcium channels by the spider toxin omega-Aga-toxin IIIA: advantages over 1,4-dihydropyridines.

Cohen CJ, Ertel EA, Smith MM, Venema VJ, Adams ME, Leibowitz MD.

Mol Pharmacol. 1992 Dec;42(6):947-51.

PMID:
1480135
30.

Modulation of M current in frog sympathetic ganglion cells.

Bosma MM, Bernheim L, Leibowitz MD, Pfaffinger PJ, Hille B.

Soc Gen Physiol Ser. 1990;45:43-59. Review. No abstract available.

PMID:
2165636
31.

Agonists that suppress M-current elicit phosphoinositide turnover and Ca2+ transients, but these events do not explain M-current suppression.

Pfaffinger PJ, Leibowitz MD, Subers EM, Nathanson NM, Almers W, Hille B.

Neuron. 1988 Aug;1(6):477-84.

PMID:
2483099
32.

A high-conductance anion channel in adult amphibian skeletal muscle.

Woll KH, Leibowitz MD, Neumcke B, Hille B.

Pflugers Arch. 1987 Dec;410(6):632-40.

PMID:
2453021
33.

A polisher for patch pipets.

Leibowitz MD, Dionne VE.

Pflugers Arch. 1987 Oct;410(3):338-9.

PMID:
2446258
34.

Electrophysiological comparison of insecticide and alkaloid agonists of Na channels.

Leibowitz MD, Schwarz JR, Holan G, Hille B.

J Gen Physiol. 1987 Jul;90(1):75-93.

35.

State-dependent modification of sodium channels by lipid-soluble agonists.

Hille B, Leibowitz MD, Sutro JB, Schwarz JR, Holan G.

Soc Gen Physiol Ser. 1987;41:109-24. No abstract available.

PMID:
2436305
36.

Voltage-dependent gating of veratridine-modified Na channels.

Leibowitz MD, Sutro JB, Hille B.

J Gen Physiol. 1986 Jan;87(1):25-46.

37.

Single-channel acetylcholine receptor kinetics.

Leibowitz MD, Dionne VE.

Biophys J. 1984 Jan;45(1):153-63.

38.
39.

Partial purification and study of pollen glucuronokinase.

Leibowitz MD, Dickinson DB, Loewus FA, Loewus M.

Arch Biochem Biophys. 1977 Mar;179(2):559-64. No abstract available.

PMID:
192151

Supplemental Content

Loading ...
Support Center